Akarna Therapeutics akarna.com


Public lists: Pharma Startups (4733)

Akarna Therapeutics develops novel small molecule therapeutics that target inflammatory and fibrotic diseases. Its lead program is a FXR agonist for the treatment of non-alcoholic steatohepatitis (NASH).

Akarna Therapeutics develops novel small molecule therapeutics that target inflammatory and fibrotic diseases. Its lead program is a FXR agonist for the treatment of non-alcoholic steatohepatitis (NASH).

Company (Acquired)

Phone:

Fax:

St. John’s Innovation Center
Cowley Road
Cambridge, CB4 0WS
United Kingdom

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Akarna Therapeutics $15M Sep 20, 2016

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Akarna Therapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 3 investors
There is no Board of Directors data available for this company. Please select another tab.
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Fused bicyclic compounds for the treatment of disease Sep 25, 2017 Application
Fused bicyclic compounds for the treatment of disease Jun 22, 2017 Application
Fused bicyclic compounds for the treatment of disease May 19, 2017 Application